Issue: December 2015
December 31, 2015
2 min read

Assessing Real-world Outcomes with New HCV Regimens in 2014: HCV-TARGET Registry Findings

Issue: December 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The field of HCV treatment is rapidly evolving, with two new direct-acting antiviral agents (DAA) approved at the end of 2013 and several more approved in 2014. HCV-TARGET is an international consortium of academic and community investigators prospectively enrolling patients treated with HCV regimens that include a DAA to assess the effects of HCV therapy in the broader population. The HCV-TARGET initiative aims to continue to evaluate the safety and efficacy of HCV regimens, including a robust data set of traditionally underrepresented patient populations, such as those with cirrhosis, null responders, older adults, African Americans, Hispanics, and patients infected with mutated strains of HCV. This CME activity will consider real-world data of patients treated with new regimens to provide an understanding of how and when specific regimens are most beneficial, particularly in challenging patients with HCV genotype 1, and will review the current HCV practice guidelines and how and when to use the new treatment regimens.

Click here to see this Education Lab Activity.

Learning Objectives:

Upon completion of this activity, participants should be better able to:

  • Evaluate the 2014 recommendations of the AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C and determine how they may be used in real-world applications.
  • Evaluate real-world data, in addition to clinical trial data, for the treatment of challenging patients with genotype 1 HCV.
  • Assess the success of treatment strategies that have incorporated the use of newly approved second-generation DAA regimens in challenging patients with genotype 1 HCV.
  • Evaluate the efficacy, safety, and cost-effectiveness of the first available second-generation DAA regimens in clinical trials and in real-life scenarios in order to more effectively communicate the risk-benefit ratio to patients, as well as choose the most appropriate therapy for individual patients with HCV.


Author(s)/Faculty: David R. Nelson, MD; Ira M. Jacobson, MD; Nancy Reau, MD; Mark S. Sulkowski, MD
Source: Healio Gastroenterology Education Lab
Type: Multimedia
Articles/Items: 5
Release Date: 1/30/2015
Expiration Date: 1/29/2016
Credit Type: CME
Number of Credits: 1.75
Cost: Free
Provider: University of Cincinnati

CME Information

Provider Statement: This continuing medical education activity is provided by University of Cincinnati.
Educational Partner: Vindico Medical Education
Support Statement: We gratefully acknowledge the following company for their educational grant in support of this educational activity. Janssen Therapeutics, Division of Janssen Products, LP.
Target Audience: The intended audience for this activity is hepatologists, gastroenterologists, infectious disease specialists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.